NCT04305145

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2020-08-31Est. Completion: 2030-06-30

Enrollment target: 42 participants

Locations

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Other microbiome trials you might be interested in

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerPhase 3Recruiting

Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatm…

Anchorage, United StatesEst. completion Dec 31, 2026

View Trial →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Phase 3Recruiting

Lung Non-Small Cell CarcinomaLung Non-Small Cell Squamous Carcinoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.